RR001

Small molecule

EEIR Biotherapies s.r.l.

RR001 is one of 33 small molecule programs targeting Pancreatic Carcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Pancreatic Carcinoma

#DrugCompanyPhaseTrials

Lynparza

Gemzar

6 3

Camptosar

Pfizer

Phase 3

1 4

Eloxatin

Teva

Phase 3

1 5

Imfinzi

Folinic Acid

1 7

BMS-986205

Iressa

1 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 10

Tuoyi

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Pancreatic Carcinoma

NCT06861452

Clinical

Trials by Indication[1]

Pancreatic Carcinoma1 trial

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

Recruiting·EEIR Biotherapies s.r.l.·Phase 1/2·NCT06861452·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RR001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RR001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RR001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EIR Biotherapies s.r.l. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EEIR Biotherapies s.r.l.

RR001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pancreatic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News